Interferons and Their Use in Persistent Viral Infections

Overview

Journal Handb Exp Pharmacol

Specialty Pharmacology

Date 2008 Dec 3

PMID 19048202

Citations 7

Authors

Stephane Chevaliez

Jean-Michel Pawlotsky

Affiliations

Soon will be listed here.

Abstract

In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindenmann. Subsequently, the IFN-alpha gene was cloned, fully sequenced and IFN-alpha was produced in recombinant form. Recombinant IFN-alpha is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.

Citing Articles

Zika Virus Pathogenesis: A Battle for Immune Evasion.

Estevez-Herrera J, Perez-Yanes S, Cabrera-Rodriguez R, Marquez-Arce D, Trujillo-Gonzalez R, Machado J Vaccines (Basel). 2021; 9(3).

PMID: 33810028 PMC: 8005041. DOI: 10.3390/vaccines9030294.

Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection.

Song J, Zhou Y, Li S, Wang B, Zheng X, Wu J PLoS One. 2014; 9(3):e90977.

PMID: 24618716 PMC: 3950299. DOI: 10.1371/journal.pone.0090977.

What are the pros and cons of the use of host-targeted agents against hepatitis C?.

Pawlotsky J Antiviral Res. 2014; 105:22-5.

PMID: 24583032 PMC: 7173253. DOI: 10.1016/j.antiviral.2014.02.008.

Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.

Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H Nat Immunol. 2013; 14(8):793-803.

PMID: 23832071 DOI: 10.1038/ni.2647.

Hepatitis C variability, patterns of resistance, and impact on therapy.

Strahotin C, Babich M Adv Virol. 2012; 2012:267483.

PMID: 22851970 PMC: 3407602. DOI: 10.1155/2012/267483.

References

van Zonneveld M, Zondervan P, Cakaloglu Y, Simon C, Akarca U, So T . Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006; 26(4):399-405. DOI: 10.1111/j.1478-3231.2006.01257.x. View

Wang T, Blatt L, Seiwert S . Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections. J Interferon Cytokine Res. 2006; 26(7):473-83. DOI: 10.1089/jir.2006.26.473. View

Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E . High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci. 2001; 45(12):2414-21. DOI: 10.1023/a:1005655428563. View

Calleri G, Cariti G, Gaiottino F, De Rosa F, Bargiacchi O, Audagnotto S . A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007; 14(2):116-21. DOI: 10.1111/j.1365-2893.2006.00802.x. View

Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M . Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25):1575-8. DOI: 10.1056/NEJM198612183152503. View

Parvez M, Sehgal D, Sarin S, Basir S, Jameel S . Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol. 2006; 12(19):3006-14. PMC: 4124373. DOI: 10.3748/wjg.v12.i19.3006. View

Niro G, Rosina F, Rizzetto M . Treatment of hepatitis D. J Viral Hepat. 2005; 12(1):2-9. DOI: 10.1111/j.1365-2893.2005.00601.x. View

Fernandez-Cruz E, Lang J, Frissen J, Furner V, Chateauvert M, Boucher C . Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group. AIDS. 1995; 9(9):1025-35. View

Martal J, Chene N, Huynh L, LHaridon R, Reinaud P, Guillomot M . IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie. 1998; 80(8-9):755-77. DOI: 10.1016/s0300-9084(99)80029-7. View

10.

Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Muh U, Welker M . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132(5):1767-77. DOI: 10.1053/j.gastro.2007.02.037. View

11.

Dooley J, Davis G, Peters M, WAGGONER J, Goodman Z, Hoofnagle J . Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology. 1986; 90(1):150-7. DOI: 10.1016/0016-5085(86)90087-9. View

12.

Fischl M, Richman D, Saag M, Meng T, Squires K, Holden-Wiltse J . Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16(4):247-53. DOI: 10.1097/00042560-199712010-00005. View

13.

Bocher W, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M . Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int. 2006; 26(3):319-25. DOI: 10.1111/j.1478-3231.2005.01239.x. View

14.

Coccia E, Krust B, Hovanessian A . Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem. 1994; 269(37):23087-94. View

15.

Gack M, Shin Y, Joo C, Urano T, Liang C, Sun L . TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007; 446(7138):916-920. DOI: 10.1038/nature05732. View

16.

Wong D, Cheung A, ORourke K, Naylor C, Detsky A, Heathcote J . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119(4):312-23. DOI: 10.7326/0003-4819-119-4-199308150-00011. View

17.

Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Toruner M . Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat. 2005; 12(3):262-8. DOI: 10.1111/j.1365-2893.2005.00566.x. View

18.

Flink H, van Zonneveld M, Hansen B, de Man R, Schalm S, Janssen H . Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006; 101(2):297-303. DOI: 10.1111/j.1572-0241.2006.00418.x. View

19.

LaFleur D, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M . Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001; 276(43):39765-71. DOI: 10.1074/jbc.M102502200. View

20.

Barbaro G, ZECHINI F, Pellicelli A, Francavilla R, Scotto G, Bacca D . Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001; 35(3):406-11. DOI: 10.1016/s0168-8278(01)00145-3. View